Compare NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) (NWG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

NatWest Group (NWG) trades at $17.65, up 2.38% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a low P/E of 8.94 and robust profitability with a net income margin of 36.24%. Recent earnings have consistently beaten expectations, and analyst sentiment is positive, with a 'Moderate Buy' consensus. The company has upgraded its 2026 guidance and accelerated share buybacks, supported by healthy revenue growth and improving deposit margins.

The outlook for NWG is favorable, driven by earnings momentum and supportive analyst coverage, though risks include negative cash flow trends and potential regulatory scrutiny. The stock presents a value opportunity given its attractive valuation and strong return on equity, but investors should monitor execution on profitability targets and macroeconomic impacts on the banking sector.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.